Anadys Reports Net Loss of $6.5 Million 2ND QTR 2009 (Financial Report‪)‬

Anadys Pharmaceuticals, Inc. (NASDAQ:ANDS), San Diego, Calif., a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, has reported its financial results and program highlights for the second quarter ended June 30, 2009. "With our enhanced cash position, reduced cost structure and Phase II protocol allowance from the FDA, we are well positioned to continue advancing the development of ANA598 as a treatment for chronic hepatitis C," said Steve Worland, Ph.D., president and CEO of Anadys. "ANA598 has demonstrated potent antiviral activity and good tolerability in Phase I, as well as preclinical properties indicative of likely synergy when used clinically in combination regimens. The upcoming Phase II trial has several important elements, including twelve weeks of ANA598 combination treatment and a randomized exploration of shortening the overall duration of HCV therapy in conjunction with ANA598 treatment. We look forward to receiving the first data from this trial by year-end 2009 and additional data in the first half of 2010."